- Home
- NCPL vs ELEV Comparison
NCPL vs ELEV Comparison
Compare NCPL & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCPL
- ELEV
- Stock Information
- Founded
- NCPL 1984
- ELEV 2019
- Country
- NCPL United States
- ELEV United States
- Employees
- NCPL N/A
- ELEV N/A
- Industry
- NCPL Investment Managers
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- NCPL Finance
- ELEV Health Care
- Exchange
- NCPL Nasdaq
- ELEV Nasdaq
- Market Cap
- NCPL 19.3M
- ELEV 22.6M
- IPO Year
- NCPL N/A
- ELEV 2021
- Fundamental
- Price
- NCPL $3.33
- ELEV $0.37
- Analyst Decision
- NCPL
- ELEV Hold
- Analyst Count
- NCPL 0
- ELEV 6
- Target Price
- NCPL N/A
- ELEV $1.77
- AVG Volume (30 Days)
- NCPL 1.1M
- ELEV 956.9K
- Earning Date
- NCPL 09-15-2025
- ELEV 08-05-2025
- Dividend Yield
- NCPL N/A
- ELEV N/A
- EPS Growth
- NCPL N/A
- ELEV N/A
- EPS
- NCPL N/A
- ELEV N/A
- Revenue
- NCPL $812,612.00
- ELEV N/A
- Revenue This Year
- NCPL N/A
- ELEV N/A
- Revenue Next Year
- NCPL $101.16
- ELEV N/A
- P/E Ratio
- NCPL N/A
- ELEV N/A
- Revenue Growth
- NCPL N/A
- ELEV N/A
- 52 Week Low
- NCPL $1.41
- ELEV $0.22
- 52 Week High
- NCPL $11.90
- ELEV $3.09
- Technical
- Relative Strength Index (RSI)
- NCPL 38.02
- ELEV 51.24
- Support Level
- NCPL $2.85
- ELEV $0.37
- Resistance Level
- NCPL $5.14
- ELEV $0.39
- Average True Range (ATR)
- NCPL 1.30
- ELEV 0.01
- MACD
- NCPL -0.57
- ELEV -0.00
- Stochastic Oscillator
- NCPL 2.80
- ELEV 37.04
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.